Biogen (BIIB, $288.04) beats Q3 earnings and revenue estimates; new data revives possibility of Alzheimer’s therapy
Biogen Inc. topped analysts’ estimates in both earnings and revenue, while also indicating renewed hope for a Alzheimer’s therapy.
The biotech company's third-quarter 2019 earnings per share of $9.17 beat the Zacks Consensus Estimate of $8.28. Earnings rose +24% year over year.
The company’s sales for the quarter increased +5% year-over-year to $3.6 billion, surpassing Zacks Consensus Estimate of $3.53 billion.
Biogen’s product revenue increased +4% year-over-year for the quarter, while its royalty from sales of Roche’s MS drug, Ocrevus surged +37% year-over-year. Revenues from Biogen’s share of Rituxan and Gazyva operating profits increased +9%. Other revenues declined -26%.
The company’s MS revenues including Ocrevus royalties, increased +2% .
Spinal Muscular Atrophy drug Spinraza sales rose +17% year-over-year. The number of patients on Spinraza grew approximately 3% in the U.S., and 18% outside the United States quarter-over-quarter.
Combined interferon revenues (Avonex and Plegridy) fell -10% year over year.
In Biosimilars (Samsung Bioepis, the joint venture between Biogen and Samsung BioLogics), BENEPALI revenue fell -6% y-o-y, IMRALDI which was launched in mid-October last year had a +4% growth quarter-over-quarter, while FLIXABI grew +63% year-over-year.
A major potential breakthrough for Biogen could be coming with new data revealing that aducanumab is pharmacologically and clinically active as determined by dose-dependent effects in reducing accumulation of amyloid, a kind of protein, in the arteries of the brain. Based on this data, Biogen plans to submit a biologics license application (BLA) seeking approval of aducanumab to the FDA in early 2020.
Momentum Indicator for BIIB turns positive, indicating new upward trend
BIIB saw its Momentum Indicator move above the 0 level on July 02, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for BIIB just turned positive on July 02, 2025. Looking at past instances where BIIB's MACD turned positive, the stock continued to rise in of 55 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BIIB advanced for three days, in of 257 cases, the price rose further within the following month. The odds of a continued upward trend are .
BIIB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 138 cases where BIIB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIIB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BIIB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.110) is normal, around the industry mean (5.632). P/E Ratio (26.955) is within average values for comparable stocks, (48.974). BIIB's Projected Growth (PEG Ratio) (8.807) is slightly higher than the industry average of (3.004). Dividend Yield (0.000) settles around the average of (0.161) among similar stocks. P/S Ratio (3.181) is also within normal values, averaging (3.643).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIIB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of therapies for people living with neurological, autoimmune and hematologic disorders
Industry PharmaceuticalsMajor
Advertisement